RESPIRATORY SYNCYTIAL VIRUS INFECTION
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTION trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-in-One shot tested to protect seniors from common respiratory viruses
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine designed to protect against two common respiratory viruses, RSV and human metapneumovirus (hMPV), in adults aged 60 and older. Researchers gave 646 healthy participants a single shot to check for safety and to see if it triggered a strong immune re…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:33 UTC
-
Scientists test if new baby RSV vaccine can spread to others
⭐️ VACCINE ⭐️ CompletedThis study tested a new nasal spray vaccine designed to protect infants and toddlers from Respiratory Syncytial Virus (RSV). Researchers gave the vaccine to 80 healthy children aged 6 to 24 months in Puerto Rico to see if the weakened virus in the vaccine could spread to other ch…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 27, 2026 12:41 UTC
-
Scientists test nasal spray vaccine to shield babies from common RSV virus
⭐️ VACCINE ⭐️ CompletedThis study tested a new live but weakened RSV vaccine given as a nasal spray to see if it was safe and could trigger a protective immune response in young children. It involved 259 infants and toddlers aged 6 to 18 months. The main goals were to check for side effects and measure…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 27, 2026 12:39 UTC
-
New mRNA vaccine targets two major respiratory viruses in first human test
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested the safety and immune response of a new mRNA vaccine designed to prevent serious lung infections caused by RSV and human metapneumovirus (hMPV). It involved 558 healthy adults, including people aged 60 and older, who received one of several different…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:15 UTC
-
Breakthrough shot tested to shield babies from dangerous RSV
Prevention CompletedThis study tested a single shot called clesrovimab (MK-1654) to see if it could prevent serious lower respiratory infections caused by RSV in healthy babies. Over 3,600 infants, including those born prematurely, received either the shot or a placebo. The main goal was to see if t…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Mar 30, 2026 14:32 UTC